Prevalence and severity of pruritus in cutaneous T cell lymphoma
Authors:
- 12 July 2012
- journal article
- other
- Published by Wiley in International Journal of Dermatology
- Vol. 51 (8) , 930-934
Abstract
Background The most common types of cutaneous T cell lymphoma (CTCL) are mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS). One of the hallmarks of MF and SS is pruritus that rarely responds to treatment. Little is known about the prevalence and severity of pruritus in MF and SS.Objectives A retrospective analysis was performed to assess the prevalence and severity of pruritus in MF and SS.Methods This study compared self‐reported pruritus in early‐stage (stage Ia–IIa) and late‐stage (stage IIb–IVb) disease, and in MF and SS, in patients presenting at our CTCL clinic between January 1, 2006, and June 30, 2010.Results Of the 551 eligible patients, 486 reported baseline pruritus values. Overall, 373 patients had early‐stage disease, 113 had late‐stage disease, and 72 had SS. The prevalence of pruritus was 66% in all patients, 62% in patients with early‐stage disease, 83% in those with late‐stage disease, 61% in those with MF, and 94% in those with SS. Mean pruritus values out of 10 were: 4.2 [standard error of the mean (SEM) = 0.18] in all patients; 3.4 (SEM = 0.19) in patients with early‐stage disease; 6.6 (SEM = 0.36) in those with late‐stage disease; 3.6 (SEM = 0.18) in MF patients, and 7.7 (SEM = 0.37) in SS patients. Differences between early‐ and late‐stage disease, and MF and SS, were statistically significant (P < 0.001).Conclusions Pruritus affects a large proportion of patients with CTCL and is significantly more severe in late‐ than in early‐stage disease and in SS than in MF. Little information exists on the full range of the symptom burden on the patient. This aspect of patient care requires further exploration.Keywords
This publication has 24 references indexed in Scilit:
- Antipruritic treatment with systemic μ-opioid receptor antagonists: A reviewJournal of the American Academy of Dermatology, 2010
- Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviorsBlood, 2010
- Current and Emerging Treatment Strategies for Cutaneous T-cell LymphomaDrugs, 2010
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndromeBritish Journal of Dermatology, 2008
- Why Are Quality of Life Instruments Not Recognized as Reference Measures in Therapeutic Trials of Chronic Skin Disorders?Journal of Investigative Dermatology, 2007
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Significant impact of cutaneous T‐cell lymphoma on patients' quality of lifeCancer, 2006
- Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitisBritish Journal of Dermatology, 2005
- A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapyBritish Journal of Dermatology, 2002